Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Riga Stradiņš Univer...arrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
addClaim

This Research product is the result of merged Research products in OpenAIRE.

You have already added 0 works in your ORCID record related to the merged Research product.
addClaim

This Research product is the result of merged Research products in OpenAIRE.

You have already added 0 works in your ORCID record related to the merged Research product.

Strategies to manage hepatitis C virus infection disease burden - Volume 3

Authors: Alfaleh, F. Z.; Nugrahini, N.; Matičič, M.; Tolmane, I.; Alzaabi, M.; Hajarizadeh, B.; Valantinas, J.; +113 Authors

Strategies to manage hepatitis C virus infection disease burden - Volume 3

Abstract

Publisher Copyright: © 2015 John Wiley & Sons Ltd. The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries in Europe, the Middle East and Asia, and the relative impact of two scenarios was considered: increased treatment efficacy while holding the annual number of treated patients constant and increased treatment efficacy and an increased annual number of treated patients. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. A 90% reduction in total HCV infections within 15 years is feasible in most countries studied, but it required a coordinated effort to introduce harm reduction programmes to reduce new infections, screening to identify those already infected and treatment with high cure rate therapies. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. Among European countries, the majority of patients were born between 1940 and 1985. A wider range of birth cohorts was seen in the Middle East and Asia (between 1925 and 1995). Peer reviewed

Country
Latvia
Keywords

hepatitis C virus, 1.6 Biological sciences, treatment, 3.1 Basic medicine, Hepatology, diagnosis, prevalence, scenarios, 1.1. Scientific article indexed in Web of Science and/or Scopus database, mortality, disease burden, elimination, Infectious Diseases, SDG 3 - Good Health and Well-being, Virology, incidence, epidemiology, hepatitis C, strategy

18 references, page 1 of 2

1 Sibley A, Han KH, Abourached A et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 3. J Viral Hepat 2015; 22(Suppl 4): 21-41.

2 Hatzakis A, Chulanov V, Gadano AC et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2. J Viral Hepat 2015; 22(Suppl 1): 26-45.

3 Razavi H, Waked I, Sarrazin C et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014; 21 (Suppl 1): 34-59.

4 Evon DM, Verma A, Dougherty KA et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci 2007; 52(11): 3251-3258.

5 Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005; 20(8): 754-758.

6 North CS, Hong BA, Adewuyi SA et al. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. Gen Hosp Psychiatry 2013; 35 (2): 122-128.

7 Liakina V, Hamid S, Tanaka J et al. Historical epidemiology of hepatitis C virus (HCV) in select countriesvolume 3. J Viral Hepat 2015; 22 (Suppl 4): 4-20.

8 Olafsson S, Bergmann O, Jonasson J, Ormarsdottir S. Major increase in the incidence of cirrhosis in Iceland - results of a nationwide population based study. Hepatology 2011; 54 (S1): 587A-588A.

9 Tanaka J, Koyama T, Mizui M et al. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and areaspecific prevalence on the national scale. Intervirology 2011; 54(4): 185-195.

10 Tanaka Y, Hanada K, Mizokami M et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A 2002; 99 (24): 15584-15589.

  • BIP!
    Impact byBIP!
    citations
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    0
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    Average
  • citations
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    0
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    Average
    Powered byBIP!BIP!
Powered by OpenAIRE graph
Found an issue? Give us feedback
citations
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
0
Average
Average
Average
moresidebar

Do the share buttons not appear? Please make sure, any blocking addon is disabled, and then reload the page.